|
|
Latest Lung Cancer: Non-Small Cell News
Addition of Sutent to Tarceva Does Not Improve Overall Survival with Advanced Non-Small Cell Lung Cancer (9/7/2010)
Among patients with previously treated non-small cell lung cancer, the combination of Sutent® (sunitinib) and Tarceva® (erlotinib) delays cancer progression but does not improve overall survival compared with Tarceva alone.
Early Palliative Care Linked with Longer Lung Cancer Survival (9/1/2010)
Palliative care is care that is focused on symptom management, psychosocial issues, decision-making, and quality of life. Among patients with newly diagnosed, metastatic, non-small cell lung cancer, the addition of early palliative care to standard cancer treatment resulted in better quality of life and mood and longer survival than standard treatment alone. These results were published in the New England Journal of Medicine.
Estrogen Alone Does Not Increase Lung Cancer Incidence or Mortality in Postmenopausal Women (8/30/2010)
Among postmenopausal women, hormone therapy with estrogen alone does not appear to increase the risk of getting or dying from lung cancer. These results were published in the Journal of the National Cancer Institute.
Study Evaluates Safety of Avastin and Chemotherapy in Non–Squamous Non–Small Cell Lung Cancer (8/3/2010)
A large Phase IV study confirms that the safety and efficacy reported in Phase III trials of Avastin® (bevacizumab) plus standard chemotherapy for patients with advanced non-squamous non-small cell lung cancer translate into the clinical practice setting. These findings were recently published in the journal The Lancet Oncology.
Vitamin B6 Associated with Lower Risk of Lung Cancer (6/28/2010)
Individuals with high blood levels of vitamin B6 may be less likely to develop lung cancer compared with their counterparts with lower vitamin B6 levels, according to the results of a study published in the Journal of the American Medical Association.
Lung Cancer: Non-Small Cell News By Topic
Lung Cancer: Non-Small Cell - Screening/PreventionEstrogen Alone Does Not Increase Lung Cancer Incidence or Mortality in Postmenopausal Women (8/30/2010)
Among postmenopausal women, hormone therapy with estrogen alone does not appear to increase the risk of getting or dying from lung cancer. These results were published in the Journal of the National Cancer Institute.
Vitamin B6 Associated with Lower Risk of Lung Cancer (6/28/2010)
Individuals with high blood levels of vitamin B6 may be less likely to develop lung cancer compared with their counterparts with lower vitamin B6 levels, according to the results of a study published in the Journal of the American Medical Association.
Some Blood Pressure Drugs May Raise Cancer Risk (6/23/2010)
It appears that angiotensin-receptor blockers (ARBs), a widely used class of blood pressure drugs, may slightly increase the risk of cancer. These findings were published in the Lancet Oncology.
Lung Cancer Risk and Traffic-related Air Pollution (5/20/2010)
Researchers report a modest association between air pollution resulting from traffic and risk of lung cancer. These findings were recently published in the journal Cancer Epidemiology, Biomarkers & Prevention.
High Rate of False-positive Results in Lung Cancer Screening with CT Scan (4/28/2010)
Screening for lung cancer using computed tomography (CT) scans can yield a high rate of false-positive results, according to a study published in the Annals of Internal Medicine. False-positive results are risky because they may lead to invasive follow-up testing, financial burden, and anxiety.
Lung Cancer: Non-Small Cell - Stages I-IIIASelenium Does Not Prevent Second Lung Cancers in Patients with Early Non-small Cell Lung Cancer (6/8/2010)
Supplementation with selenium in patients with Stage IA and IB non-small cell lung cancer does not appear to prevent a second primary lung cancer from developing, according to the results of a Phase III study presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Stereotactic Radiation May Benefit Early Non–Small Cell Lung Cancer Patients Ineligible for Surgery (5/25/2010)
Patients with early-stage non–small cell lung cancer (NSCLC) who were medically unable to undergo surgery to remove their cancer had a 55.8% overall survival at three years following stereotactic body radiation therapy. These findings were recently published in the Journal of the American Medical Association.
Phase III Trial Evaluates Preoperative Chemotherapy for Non–Small Cell Lung Cancer (5/21/2010)
A Phase III clinical trial of preoperative chemotherapy for non–small cell lung cancer did not provide definitive evidence of a benefit. The results of this prematurely closed study were recently published in the Journal of Clinical Oncology.
Most Survivors of Lung and Colorectal Cancer Keep Their Jobs (4/14/2010)
Among people diagnosed with nonmetastatic lung or colorectal cancer, the majority return to work, according to a study recently published in Journal of Clinical Oncology. Those who do leave the workforce tend to have worse prognoses and lower socioeconomic status.
Concurrent Radiochemotherapy Improves Survival in NSCLC (4/12/2010)
Concurrent chemotherapy delivered with radiation decreased locoregional progression and improved survival in locally advanced non–small cell lung cancer compared with sequential chemotherapy delivered before and/or after radiation. The results of this study were published early online in the Journal of Clinical Oncology.
Lung Cancer: Non-Small Cell - Stages IIIB-IVAddition of Sutent to Tarceva Does Not Improve Overall Survival with Advanced Non-Small Cell Lung Cancer (9/7/2010)
Among patients with previously treated non-small cell lung cancer, the combination of Sutent® (sunitinib) and Tarceva® (erlotinib) delays cancer progression but does not improve overall survival compared with Tarceva alone.
Early Palliative Care Linked with Longer Lung Cancer Survival (9/1/2010)
Palliative care is care that is focused on symptom management, psychosocial issues, decision-making, and quality of life. Among patients with newly diagnosed, metastatic, non-small cell lung cancer, the addition of early palliative care to standard cancer treatment resulted in better quality of life and mood and longer survival than standard treatment alone. These results were published in the New England Journal of Medicine.
Study Evaluates Safety of Avastin and Chemotherapy in Non–Squamous Non–Small Cell Lung Cancer (8/3/2010)
A large Phase IV study confirms that the safety and efficacy reported in Phase III trials of Avastin® (bevacizumab) plus standard chemotherapy for patients with advanced non-squamous non-small cell lung cancer translate into the clinical practice setting. These findings were recently published in the journal The Lancet Oncology.
Large Study Confirms that Vandetanib Is Active in Previously Treated Non–Small Cell Lung Cancer (6/15/2010)
The combination of vandetanib plus Taxotere resulted in longer survival without cancer progression than Taxotere alone among patients with previously-treated non–small cell lung cancer (NSCLC). These findings were recently published in the journal The Lancet Oncology.
Combination Chemotherapy Improves Survival in Elderly Lung Cancer Patients (6/7/2010)
Among patients age 70 or older with advanced non-small cell lung cancer (NSCLC), treatment with a combination of two chemotherapy drugs—paclitaxel and carboplatin—results in better progression-free and overall survival than treatment with single-agent chemotherapy. The results of this Phase III clinical trial will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Lung Cancer: Non-Small Cell - RecurrentAddition of Sutent to Tarceva Does Not Improve Overall Survival with Advanced Non-Small Cell Lung Cancer (9/7/2010)
Among patients with previously treated non-small cell lung cancer, the combination of Sutent® (sunitinib) and Tarceva® (erlotinib) delays cancer progression but does not improve overall survival compared with Tarceva alone.
Study Evaluates Safety of Avastin and Chemotherapy in Non–Squamous Non–Small Cell Lung Cancer (8/3/2010)
A large Phase IV study confirms that the safety and efficacy reported in Phase III trials of Avastin® (bevacizumab) plus standard chemotherapy for patients with advanced non-squamous non-small cell lung cancer translate into the clinical practice setting. These findings were recently published in the journal The Lancet Oncology.
Large Study Confirms that Vandetanib Is Active in Previously Treated Non–Small Cell Lung Cancer (6/15/2010)
The combination of vandetanib plus Taxotere resulted in longer survival without cancer progression than Taxotere alone among patients with previously-treated non–small cell lung cancer (NSCLC). These findings were recently published in the journal The Lancet Oncology.
Addition of Avastin® to Tarceva® Does Not Appear to Improve Survival in Patients with Advanced Non–Small Cell Lung Cancer (10/6/2008)
According to the results of a Phase III clinical trial, treatment with Avastin® (bevacizumab) plus Tarceva® (erlotinib) did not result in better survival than treatment with Tarceva alone among patients with advanced non–small cell lung cancer (NSCLC) whose disease had progressed following platinum-based chemotherapy. These results were recently published in a press release by Genentech.
Bone Marker Associated with Survival in Breast, Prostate, and Lung Cancers (6/23/2008)
The bone marker N-telopeptide of type I collagen (NTX) is associated with skeletal-related events and survival among patients with cancer that has spread to the bone (bone metastases). Improved outcomes may be achieved by reducing these markers through treatment with agents such as Zometa® (zoledronic acid). These results were recently published in the journal Cancer.
|
|
